Publications by authors named "Mariafrancesca Loria"

Background/aim: Prevalence of gastroduodenal endoscopic and histological lesions may modify over time due to different factors. We assessed both macroscopic and histological lesions currently detected at upper endoscopy performed in routine practice.

Patients And Methods: Clinical, endoscopic, and histological data of consecutive adult patients referred for upper endoscopy in the 28 participating centres were analysed.

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on evaluating the prevalence of endoscopic and histological changes in elderly patients (over 65) undergoing upper endoscopy.
  • Out of 1,336 patients, 31.4% had at least one macroscopic lesion, with erosive gastritis and erosive oesophagitis being the most common findings.
  • The results indicated that the occurrence of endoscopic lesions was linked to male gender and alarm symptoms, while proton pump inhibitor (PPI) therapy reduced the likelihood of such lesions.
View Article and Find Full Text PDF

Background And Aims: International guidelines advise improving esophagogastroduodenoscopy (EGD) quality in Western countries, where gastric cancer is still diagnosed in advanced stages. This nationwide study investigated some indicators for the quality of EGD performed in endoscopic centers in Italy.

Methods: Clinical, endoscopic, and procedural data of consecutive EGDs performed in one month in the participating centers were reviewed and collected in a specific database.

View Article and Find Full Text PDF

Background: Probiotic supplementation to antibiotic regimens against infection has been proposed to improve eradication rate and to decrease detrimental effects on gut microbiota.

Aims: To evaluate microbiota modifications due to a low-dose quadruple therapy with bismuth or .

Methods: Forty-six patients infected with were prospectively enrolled in a single-centre, randomized controlled trial to receive b.

View Article and Find Full Text PDF

Background: Bismuth is no longer available in Europe except as part of combination therapy. Lactobacillus reuteri has also been used as an adjuvant for Helicobacter pylori therapy. We aimed to investigate the efficacy of a b.

View Article and Find Full Text PDF